Biomarkers associated with stroke risk in atrial fibrillation.

By 20 Ιουλίου 2017 10 Απριλίου, 2019 Δημοσιεύσεις

Δημοσίευση στις 2017/7/20 στο PubMed: https://www.ncbi.nlm.nih.gov/pubmed/28721825

Ioannou A, Papageorgiou N, Falconer D, Rehal O, Sewart E, Zacharia E, Toutouzas K, Vlachopoulos C, Siasos G, Tsioufis C, Tousoulis D.

Abstract

Atrial fibrillation is associated with increased risk for cardioembolic stroke. The risk of cardioembolism is not adequately reduced with the administration of oral anticoagulants, since a number of patients continue to experience thromboembolic events despite receiving anti-thrombotic treatment. Several biomarkers have been proposed to predict cardioembolic stroke in patients with atrial fibrillation. Some of them are already used in the clinical practice, such as D-Dimers, Troponin and brain natriuretic peptide. Novel ones such as the inflammatory growth differentiation factor-15, appear to be promising, while the role of micro-RNAs and genetics appear to be useful as well. Even though these biomarkers are associated with an increased risk for thromboembolism, they cannot accurately predict future events. In this light, the use of a scoring system, that would incorporate both circulating biomarkers and clinical factors, might be more useful. Therefore, further research is required to establish a multifactorial scoring system that will identify patients at high-risk for thromboembolism, who will benefit from more intensive treatment and monitoring.

error: